<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440566</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/06</org_study_id>
    <nct_id>NCT04440566</nct_id>
  </id_info>
  <brief_title>O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus</brief_title>
  <acronym>METABOLUPS</acronym>
  <official_title>O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic&#xD;
      lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in&#xD;
      SLE with potential for the discovery of new therapeutic strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a rare and potentially life-threatening auto-immune&#xD;
      systemic disease. There is an urgent need for better comprehension of the physiopathology of&#xD;
      the disease and to discover new therapeutic pathways.&#xD;
&#xD;
      The hexosamine biosynthesis pathway, or HBP, is an important regulator of immunity and&#xD;
      results in a post-transductional modification of proteins called O-GlcNAcylation and involved&#xD;
      in inflammation and immunity.&#xD;
&#xD;
      There is a very unbalanced sex ratio in favor of women in SLE suggesting a role of the X&#xD;
      chromosome in the physiopathology of the disease. The human OGT gene (a key O-GlcNAcylation&#xD;
      enzyme) is localized on the X chromosome, near the XIST gene responsible for the inactivation&#xD;
      of one X chromosome by methylation.&#xD;
&#xD;
      Moreover, genes encoding CD40L, CXCR3 and OGT have been shown to be demethylated and&#xD;
      overexpressed in T cells of women with systemic systemic lupus erythematosus compared to men&#xD;
      with the same pathology.&#xD;
&#xD;
      The investigators hypothesize that O-GlcNAcylation is increased in the effector lymphocytes&#xD;
      of SLE patients and involved in the pathophysiology of the disease. Therefore, inhibiting&#xD;
      O-GlcNAcylation may be a promising therapeutic option in SLE.&#xD;
&#xD;
      This study will recruit 100 patients with SLE followed in Bordeaux University Hospital. Among&#xD;
      classical disease activity information, blood samples will be collected at study visit to&#xD;
      study O-GlcNAcylation levels in immune cells. Fundamental research will be realized on&#xD;
      patients' sample.&#xD;
&#xD;
      Clinical and biological disease activity, treatment and outcomes will be studied in&#xD;
      correlation with O-GlcNAcylation levels. Patients will be included within their usual&#xD;
      follow-up. No extra visit will be needed and blood samples will be drawn at the same times as&#xD;
      those drawn for clinical purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of O-GlcNAcylation level in the blood samples of SLE</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
    <description>score (Min value: 0 - Max value: 105), with higher values mean higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to British Lupus Assessment Group Index 2004 (BILAG-2004)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
    <description>(Min value : 0 - Max value : 4), with higher values mean more severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of OGT biallelic expression in the blood samples of SLE</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient aged over 18 years old&#xD;
&#xD;
          -  Diagnosis of systemic lupus erythematosus&#xD;
&#xD;
          -  Affiliated person or beneficiary of a social security scheme.&#xD;
&#xD;
          -  Having signed an informed consent (at the latest on the day of inclusion and before&#xD;
             any examination required by research).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women,&#xD;
&#xD;
          -  Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick BLANCO, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick BLANCO, Prof</last_name>
    <phone>(0)5 56 79 56 45</phone>
    <phone_ext>+33</phone_ext>
    <email>patrick.blanco@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas BARNETCHE, PhD</last_name>
    <phone>(0)5 57 82 04 93</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.barnetche@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - Service d'Immunologie et Immunogénétique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick BLANCO, Prof</last_name>
      <phone>(0)5 56 79 56 45</phone>
      <phone_ext>+33</phone_ext>
      <email>patrick.blanco@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas BARNETCHE, PhD</last_name>
      <phone>(0)5.57.82.04.93</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.barnetche@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick BLANCO, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel COUZI, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DUFFAU, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien SENESCHAL, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>autoimmunity</keyword>
  <keyword>O-GlcNAcylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

